Navigation Links
New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
Date:10/24/2007

Study Confirms Role of AMBIEN CR in Effectively Managing Insomnia to

Improve Quantity and Quality of Work Performance

BRIDGEWATER, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Sanofi-aventis today announced results from a new study that showed patients with chronic insomnia who were treated with 12.5 mg of AMBIEN CR(R) (zolpidem tartrate extended- release) tablets CIV experienced significant improvements in two key parameters of work performance - output and time management - over a period of 12 weeks compared with patients taking placebo. Patients with chronic insomnia can have a higher frequency of work-related problems including absenteeism, an increased rate of accidents, difficulty performing duties and less job satisfaction. These results, which were part of a larger study that evaluated the efficacy and safety of AMBIEN CR when taken as needed, were recently presented at the 20th Annual U.S. Psychiatric and Mental Health Congress in Orlando, Florida.

The multi-center, phase IIIb, randomized, double-blind study included 728 patients with chronic primary insomnia (478 treated with AMBIEN CR and 250 treated with placebo). Treatment with AMBIEN CR showed significantly higher improvement from baseline in work tasks at week 12 in Work Limitation Questionnaire (WLQ) for both Time Management Scale (- 7.39 difference; p < 0.001) and the Output Scale (- 4.8 difference; p = 0.0076) compared to placebo, which was confirmed by an effect size analysis. The majority of adverse events experienced by patients in the study were mild to moderate in intensity, and the most frequently reported adverse events by participants include headache, anxiety and somnolence.

"These new data add to the growing body of evidence that shows that the treatment of chronic insomnia can improve next day functioning," said Milton Erman, MD, chief medical officer, Avastra USA, and clinical professor of psychiatry, UCSD School of Medicine. "This study demonstrates
'/>"/>

SOURCE sanofi-aventis
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
4. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
10. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
11. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014  Cohen, Placitella & Roth, ... investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or ... period from January 31, 2011 through November 2, ... and certain of its officers and directors publically ... of Sections 10(b) and 20(a) of the Securities ...
(Date:11/26/2014)... 2014   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... CEO of Regulus, will present a company overview at ... at the New York Palace Hotel on Wednesday, December ... be webcast at the time of the presentation and ...
(Date:11/26/2014)... -- Investor-Edge has initiated coverage on the following ... PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... ), and Theravance Inc. (NASDAQ: THRX ). Free ... http://investor-edge.com/register . On Tuesday, November 25, 2014, the ... Industrial Average edged 0.02% lower, to finish the day at ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... UBM Canon Medical Device Media Group,s ... the " Technological Advances in Implantable Devices " virtual event ... 5 p.m. Eastern.  The event is dedicated to cutting-edge trends ... conference and trade show offers the opportunity to learn from ...
... N.J., Feb. 1, 2011 Soligenix, Inc. (OTC Bulletin ... a late-stage biopharmaceutical company, announced today that it has ... and Chief Medical Officer. Dr. Horgan is a board-certified ... experience in the care of patients with inflammatory bowel ...
Cached Medicine Technology:UBM Studios Virtual Event Connects the UBM Canon Medical Device Media Group with the Medical Device Design Community 2UBM Studios Virtual Event Connects the UBM Canon Medical Device Media Group with the Medical Device Design Community 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 2Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 4
(Date:11/28/2014)... November 29, 2014 The holiday season is ... recently announced its new collection of fashionable party dresses. What’s ... off, on all these brand new outfits; the special offer ... is a renowned online supplier and it has received a ... new items are specially designed to flatter various body shapes; ...
(Date:11/28/2014)... 2014 Pathways Home Health & ... This national movement was created to encourage people to ... local charities and causes. This online event, celebrated ... kickoff of the holiday shopping season. #GivingTuesday is to ... Cyber Monday is to online commerce. , The goal ...
(Date:11/28/2014)... is always making changes to its infrastructure architecture as ... effective, and secure experience. Most recently, the company announced ... to setup local servers for each country or continent. ... the globe. , 2. The ability to setup a ... millions of users in one network. , 3. The ...
(Date:11/28/2014)... November 28, 2014 Junk-A-Car ( http://www.junkacar.com ... expanding their service offerings to help drivers, especially those ... and Washington, D.C. metropolitan areas deal with the especially ... a large part of the country. , With the ... in hundreds of totaled, crashed and junk ...
(Date:11/28/2014)... Novatus, a leading provider of contract ... provides customers with greater reporting capabilities, more searchable ... we continue to evolve and grow the Novatus ... improved performance in response to requests from our ... the enhancements that we have made to Advanced ...
Breaking Medicine News(10 mins):Health News:Trendy Party Dresses For The Coming Holiday Season From Balfleet.com 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 3Health News:Brosix Infrastructure Architecture Changes to Benefit Users 2Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2
... Swedish medical university Karolinska Institutet have determined the first ... interaction between the mammalian egg coat and sperm. The ... glimpse into the molecular architecture of animal egg coats, ... medicine and the possibility of developing novel contraceptives. , ...
... skin, intestinal mucosa or blood, have a lifespan of only ... replenishment of specialized cells is indispensable. This is the task ... cells. , Stem cells have two main characteristics: ... cell types that make up their respective tissue a ...
... AARP CEO Bill Novelli today released the following statement in ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ... are in dire economic times that will only get worse ... immediate choice is between letting these corporations go under -- ...
... 4 Cardinal Health and the,Texas Hospital Association (THA) ... to safeguard patients and combat deadly health care associated,infections ... Texas Hospital Association and its marketing subsidiary, HealthShare,recently endorsed ... help combat HAIs, improve patient care and dramatically reduce,infection-related ...
... Getting back in the gym and,erasing years of ... amounts of,weight because your health depends on it is ... joining forces with NBC,s hit weight loss,program The ... of,their lives by creating a co-branded protein product, The ...
... Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: ... Food and Drug Administration (FDA) Premarket Approval (PMA) for the ... designed to enhance cervical cancer screening for cytology laboratories using ... squamous carcinoma, adenocarcinoma and their usual precursor conditions. ...
Cached Medicine News:Health News:Crystallography reveals the 3-D structure of mammalian sperm receptor 2Health News:Dormant stem cells for emergencies 2Health News:Dormant stem cells for emergencies 3Health News:AARP: Health Care and Pension Reform Critical to Economic Recovery 2Health News:AARP: Health Care and Pension Reform Critical to Economic Recovery 3Health News:Texas Hospital Association Endorses MedMined(TM) Services to Help Fight Hospital Acquired Infections 2Health News:Texas Hospital Association Endorses MedMined(TM) Services to Help Fight Hospital Acquired Infections 3Health News:DESIGNER WHEY to Help Contestants and Fans of NBC's The Biggest Loser Shed Pounds 2Health News:DESIGNER WHEY to Help Contestants and Fans of NBC's The Biggest Loser Shed Pounds 3Health News:DESIGNER WHEY to Help Contestants and Fans of NBC's The Biggest Loser Shed Pounds 4Health News:BD Receives FDA Approval for the BD FocalPoint(TM) GS Imaging System to Enhance the Detection of Cervical Cancer 2
... a floor model centrifuge to do, but just ... PR-7000M delivers up to 50% more force in ... faster and more efficiently., Tremendous Capacity ... liters, PR-7000M accommodates 30 microplates, up to 408 ...
Inquire...
Inquire...
Inquire...
Medicine Products: